Loading clinical trials...
Loading clinical trials...
An Open-label, Randomized, Parallel-group Study to Assess the Bioequivalence of Ustekinumab Following a Single Subcutaneous Administration by Two Different Injection Devices in Healthy Participants
Conditions
Interventions
Ustekinumab
Locations
3
United States
Celerion
Tempe, Arizona, United States
Celerion
Lincoln, Nebraska, United States
PRA Health Sciences
Salt Lake City, Utah, United States
Start Date
April 14, 2021
Primary Completion Date
January 7, 2022
Completion Date
January 26, 2022
Last Updated
April 27, 2025
NCT07310264
NCT06290258
NCT06716502
NCT00090662
NCT07483606
NCT06342713
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions